Welcome to our AI Smart Industrial Channel! Click START for a short introduction.START Welcome to our AI Smart Industrial Channel! You can click or tap on the image to enlarge it, and interact with the AI icons to learn more about our company and products. Alternatively, you can explore this channel using the menu on the left.

tw

AI Language

Introduction

0/0

1

LAUNXP Biomedical Co., Ltd focuses on the development of new drugs and formulations, dedicated to meeting market demands and researching therapies for challenging-to-treat cancers. In addition to creating entirely new pharmaceuticals, our company strategically repositions FDA-approved drugs, aiming to expedite the drug development process and reduce associated costs. This approach is designed to enhance the value and market competitiveness of our products. Simultaneously, the company is actively engaged in researching virus-like particles, nanomedicine formulations, and innovative anti-cancer drugs.

Our Team

0/0

1

Our Teams

LAUNXP Biomedical Co., Ltd, led by Chairman Chiu-Heng Chen, features a specialized team with expertise in pharmacy, biochemistry, and clinical medicine. We focus on developing drug repositioning and innovative drug delivery systems. Our team is committed to providing more effective treatment options.

Operational Model

0/0

1

Operational Model

LAUNXP Biomedical Co., Ltd is primarily engaged in research and the development of early-stage clinical trials. We have a unique operational model that can be broadly divided into three parts.
1. Firstly, we introduce project sources to shorten the time required for new drug discovery.
2. Next, we introduce and undertake project development.
3. Finally, we seek suitable partners for technology licensing or collaborative development.

Our Strategy

0/0

1

Our Strategy

Our development focuses on three main areas. First, the repositioning of 505(b)(2) drugs involves using already approved marketed drugs to develop new indications and formulations. Second, the development of entirely new 505(b)(1) drugs. Third, the drug delivery system aims to enhance the targeting and precision of drug delivery.

Event Highlights

0/0

1

2015-09-24 Establishment

2017-11-08 Established in the Central Taiwan Science Park

2021-11-22Technology Transfer from the National Health Research Institutes

2022-07-28 BIO Asia–Taiwan

2022-10-12 2022 Taiwan Expo USA 2022

2023-03-22 Collaborating with China Medical University to Develop a New Drug for Lung Cancer

2023-05-31 InnoVEX 2023

2023-07-05 INTERPHEX Week Tokyo

Patents, Disease Treatment

0/0

1

LXPB5268 can enhance DR5 expression that increase TRAIL receptor-induced apoptosis in cancer cells.

LXPB5268 was originally developed as a therapeutic drug for psychiatric disorders. Through our team's research, experimental data has shown a significant tumor-inhibiting effect against breast cancer, achieving a tumor suppression rate of over 80%. It is currently planned for clinical treatment targeting triple-negative breast cancer, and patents have been obtained in multiple countries, including Taiwan, the United States, Japan, and Australia.

LXPB5268 disrupts the binding between S100B and RAGE.
LXPB5268 can induce apoptosis in cancer stem cells.

Clinical Trial Program

0/0

1

Clinical Trials of LXPB5268

Triple-negative breast cancer is a distinct subtype of breast cancer without specific receptors, making it more challenging to treat. We are actively seeking new treatment approaches for this type of breast cancer. To further validate the efficacy of LXPB5268, we are conducting a series of clinical trials. The clinical trial, initiated by the Principal Investigator (PI), has currently enrolled 8 participants, with an expected completion in the fourth quarter of 2024.

LXPB5268 Research Progress

Commercial Value

0/0

1

The Future Market Projection for LXPB5268

The estimated proportion of patients suitable for new adjuvant therapy, market penetration rate, duration of drug administration, dosage, etc., suggests a future market demand of approximately 72 to 144 million doses per year for LXPB5268.

Patents, Disease Treatment, Clinical Trials.

0/0

1

Patent Status

LXPA1788 is a novel multi-target small molecule drug acquired through technology transfer from the National Health Research Institutes. One of our target is currently unaddressed by other drugs. The clinical trials are being planned for the treatment of cancers related to the digestive system.

LXPA1788 Current Progress

Commercial Value

0/0

1

The Mechanistic Advantages of LXPA1788

Advantages:
1. Simultaneous Inhibition of Multiple Signaling Pathways Essential for Cancer Cell Proliferation:
- More effectively inhibiting the growth of cancer cells.
-Reduction in side effects.
-Overcoming drug resistance.
2. Clinical Evidence Supports the Superiority of Multi-Target Drugs Over Single-Target Drugs:
-More effective inhibition of tumor cell growth.
-Demonstrating better and broader anti-cancer effects.

Research Results

0/0

1

The Mechanism of LXPA1788
  • Multi-target kinase inhibition MOA (Aurora A/B/TrkA/Flt-3)
  • Novel inhibition of CSF1R
  • Lower drug resistance
  • Therapeutic efficacy against tumors and blood cancers
  • Excellent anti-cancer effects
  • Good drug metabolism and pharmacokinetics
  • Controlled toxicity
  • Potential first-line treatment
Compared to commercially available drugs, LXPA1788 demonstrates significantly superior results in cell experiments

Advantages of Drug Delivery Systems

0/0

1

Advantages of VLPs Drug Delivery System

1. Targeting: The drug delivery carrier can precisely transport drugs to specific organs or tumor cells.
2. TBiocompatibility: Through special design, VLPs formulations can reduce rejection reactions and lower immune system responses.
3. TLow Toxicity: Precision drug delivery helps avoid drug toxicity to normal cells, thereby minimizing side effects.
4. TLow Dosage: Accurate drug delivery to the intended destination reduces unnecessary drug consumption, achieving low-dosage, high-efficiency therapeutic effects.
5. TDrug Compliance: It can be combined with the current injection mode of chemotherapy drugs, reducing the risk of patients forgetting to take medication and delaying treatment.

Advantages

0/0

1

Drug Delivery Systems - Applications of Virus-Like Particles

Virus-like particles are applied in vaccines, including B-type Hepatitis virus (HBV), Human Papillomavirus (HPV), and Hepatitis E virus (HEV).We developed Virus-Like Particles (VLPs) serve as drug carriers capable of transporting small molecule drugs.
Advantages of virus-like particles include:

1. Nanoscale size ranging from 20-200 nm
2. Gene regulation capabilities
3. Biocompatible materials
4. Disease-targeting specificity

All Products

1 / 1 Page

Products

Introduction

AI AVATAR TOPICS

LXPB 5268

AI AVATAR TOPICS

LXPA 1788

AI AVATAR TOPICS

VLP

AI AVATAR TOPICS

Contact Us

If you have any questions, please fill in the form and submit. We will get back to you as soon as possible.

Switch Language

Switch Language

Category List

Theme Settings

Contact Us

Zoom In

Customize background color